神经病变疼痛市场规模、份额和成长分析（按类型、产品类型、手术、技术、模式、购买方式和地区划分）－2026-2033年产业预测

预计到 2024 年，神经病变疼痛市场规模将达到 28.3 亿美元，到 2025 年将达到 29.8 亿美元，到 2033 年将达到 45.1 亿美元，在预测期（2026-2033 年）内复合年增长率为 5.3%。

慢性疾病（尤其是糖尿病）盛行率的上升，以及人口老化，显着加剧了神经病变疼痛的发生率。持续不断的研发投入，致力于创新治疗方法和药物干预，进一步推动了这一趋势，并促进了市场扩张。医护人员和患者对有效管理神经病变疼痛方法的认识不断提高，凸显了这个细分市场的成长潜力。製药公司积极推出新药和治疗方法，以满足神经病变疼痛领域尚未满足的需求，旨在改善治疗效果和患者生活质量，市场因此蓬勃发展。综上所述，这些因素预示着神经病变疼痛治疗​​市场前景看好。

神经病变疼痛市场驱动因素

糖尿病、各种癌症和神经系统疾病等慢性病的日益流行，显着加剧了全球神经病变疼痛病例的增加。随着人口老化，与神经病变疼痛相关的风险因素不断上升，进一步推动了市场需求。此外，科学研究和开发的持续进步，在研发专门针对神经病变疼痛的创新药物和治疗方法发挥关键作用，从而拓展了治疗选择。慢性病盛行率的上升和医疗解决方案的进步，共同为有效应对神经病变疼痛的复杂问题创造了强劲的市场环境。

神经病变疼痛市场限制因素

神经病变疼痛市场面临的主要阻碍因素源于诊断难题和疼痛评估固有的主观性，这使得准确识别和测量神经病变疼痛变得复杂，并可能导致症状漏报和管理不善。此外，先进治疗方法和药物成本的不断上涨也会限制患者获得治疗的机会，尤其是在医疗预算紧张的地区。这些因素共同构成了有效治疗和管理神经病变疼痛的重大障碍，最终影响患者的健康和整个市场的成长。

神经病变疼痛市场趋势

神经病变疼痛市场正呈现出创新治疗方法和药物干预措施蓬勃发展的显着趋势，凸显了该领域的动态演变。这项变化源自于持续不断的研究和进步，旨在提高治疗效果和改善患者预后。此外，远端医疗正在改变神经病变疼痛管理的格局。这些技术能够提供更便利、更个人化的医疗服务，确保患者获得及时的诊断、持续的监测以及量身定制的治疗方案，从而有效满足其个别需求。创新与便利的结合正在重新定义疼痛管理策略，并有助于提高神经病变疼痛患者的生活品质。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球神经病变疼痛市场规模（按类型及复合年增长率划分）（2026-2033 年）

• 脊髓刺激（SCS）装置
• 外在周边神经刺激
• 经皮神经电刺激（TENS）装置
• 局部神经病变
• 自主神经病变
• 近端神经病变

全球神经病变疼痛市场规模（按产品类型和复合年增长率划分）（2026-2033 年）

• 可充电的
• 不可充电

全球神经病变疼痛市场规模（依治疗方法划分）及复合年增长率（2026-2033 年）

• 侵入性
• 非侵入性

全球神经病变疼痛市场规模（依技术及复合年增长率划分）（2026-2033 年）

• 经皮电刺激（TENS）
• 经颅磁刺激
• 呼吸电刺激

全球神经病变疼痛市场规模（依治疗方式及复合年增长率划分）（2026-2033 年）

• 固定类型
• 携带式的

全球神经病变疼痛市场规模（以购买方式划分）及复合年增长率（2026-2033 年）

• 市售医疗设备
• 处方笺医疗设备

全球神经病变疼痛市场规模（按疼痛类型和复合年增长率划分）（2026-2033 年）

• 週边神经病变
• 神经卡压神经病变
• 幻肢神经神经病变
• 三叉神经痛
• 带状疱疹后遗症神经痛（PHN）
• 神经病变
• 足部疼痛
• 尾骨疼痛

全球神经病变疼痛市场规模（按适应症和复合年增长率划分）（2026-2033 年）

• 脊椎管狭窄
• 化疗引起的周边神经病变
• 糖尿病神经病变
• 其他的

全球神经病变疼痛市场规模（按诊断和复合年增长率划分）（2026-2033 年）

• 影像诊断
• 血液检查
• 身体检查

全球神经病变疼痛市场规模（依治疗方法划分）及复合年增长率（2026-2033 年）

• 製药
• 多方面治疗方法

全球神经病变疼痛市场规模（按最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 诊所
• 家庭医疗保健
• 门诊手术中心
• 研究所
• 其他的

全球神经病变疼痛市场规模（依分销管道划分）及复合年增长率（2026-2033 年）

• 直接竞标
• 第三方经销商
• 其他的

全球神经病变疼痛市场规模（按地区划分）及复合年增长率（2026-2033 年）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Eli Lilly and Company（USA）
• Johnson & Johnson（USA）
• GlaxoSmithKline plc（UK）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Astellas Pharma Inc.（Japan）
• Abbott Laboratories（USA）
• Medtronic plc（Ireland）
• Boston Scientific Corporation（USA）
• Biogen Inc.（USA）
• Merck & Co., Inc.（USA）
• Bristol Myers Squibb（USA）
• AbbVie Inc.（USA）
• Grunenthal GmbH（Germany）
• AstraZeneca PLC（UK）
• Daiichi Sankyo Company, Limited（Japan）

结论与建议

Neuropathic Pain Market size was valued at USD 2.83 Billion in 2024 and is poised to grow from USD 2.98 Billion in 2025 to USD 4.51 Billion by 2033, growing at a CAGR of 5.3% during the forecast period (2026-2033).

The rising prevalence of chronic conditions, particularly diabetes, alongside an aging population, significantly contributes to the increasing incidence of neuropathic pain. This trend is further fueled by ongoing research and development efforts focused on innovative treatments and pharmaceutical interventions, fostering market expansion. Greater awareness among healthcare professionals and patients regarding effective management options for neuropathic pain highlights this growing sector. The market remains dynamic, with pharmaceutical companies actively launching new medications and therapeutic approaches aimed at addressing the unmet medical needs associated with neuropathic pain, enhancing treatment outcomes and improving patient quality of life. Overall, these factors indicate a promising outlook for the neuropathic pain treatment market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Neuropathic Pain market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Neuropathic Pain Market Segments Analysis

Global Neuropathic Pain Market is segmented by Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel and region. Based on Type, the market is segmented into Spinal Cord Stimulation (SCS) Devices, External Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Focal Neuropathy, Automatic Neuropathy and Proximal Neuropathy. Based on Product Type, the market is segmented into Rechargeable and Non-Rechargeable. Based on Procedure, the market is segmented into Invasive and Non-Invasive. Based on Technology, the market is segmented into Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation and Respiratory Electrical Stimulation. Based on Modality, the market is segmented into Stationary and Portable. Based on Mode of Purchase, the market is segmented into Over-the-Counter Devices and Prescription-Based Devices. Based on Pain Type, the market is segmented into Peripheral Neuropathy, Entrapment Neuropathy, Phantom Limb Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, Foot Pain and Coccydynia. Based on Indication, the market is segmented into Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy and Others. Based on Diagnosis, the market is segmented into Imaging, Blood Tests and Physical Examination. Based on Treatment, the market is segmented into Medications and Multimodal Therapy. Based on End User, the market is segmented into Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Research Organization and Others. Based on Distribution Channel, the market is segmented into Direct Tender, Third Party Distributor and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Neuropathic Pain Market

The rising prevalence of chronic conditions such as diabetes, various cancers, and neurological disorders has significantly contributed to a growing number of neuropathic pain cases worldwide. As populations age, the associated risk factors for neuropathic pain increase, further driving demand in the market. Additionally, continuous advancements in scientific research and pharmaceutical development play a crucial role in creating innovative medications and therapies specifically targeting neuropathic pain, thereby improving treatment options. This combination of increasing chronic illness rates and advancements in medical solutions supports a robust market environment for addressing the complexities of neuropathic pain effectively.

Restraints in the Neuropathic Pain Market

A significant constraint in the neuropathic pain market arises from the challenges in diagnosis and the inherently subjective nature of pain assessment, which complicates the accurate identification and measurement of neuropathic pain. This can result in underreporting or insufficient management of the condition. Additionally, the elevated costs associated with advanced treatment options and medications can limit accessibility, particularly in regions where healthcare budgets are constrained. These factors combined create substantial barriers to effectively addressing and managing neuropathic pain, ultimately affecting both patients' welfare and the overall market growth.

Market Trends of the Neuropathic Pain Market

The neuropathic pain market is witnessing a significant trend towards the development of innovative treatment modalities and pharmaceutical interventions, underscoring the sector's dynamic evolution. This shift is driven by ongoing research and advancements that aim to enhance therapeutic efficacy and patient outcomes. Additionally, the proliferation of telehealth services and virtual health solutions is transforming the landscape of neuropathic pain management. These technologies facilitate more accessible and personalized care, enabling patients to receive timely diagnoses, continuous monitoring, and tailored treatment plans that effectively address their unique needs. This combination of innovation and accessibility is redefining pain management strategies, fostering better quality of life for individuals affected by neuropathic pain.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Neuropathic Pain Market Size by Type & CAGR (2026-2033)

• Market Overview
• Spinal Cord Stimulation (SCS) Devices
• External Peripheral Nerve Stimulation
• Transcutaneous Electrical Nerve Stimulation (TENS) Devices
• Focal Neuropathy
• Automatic Neuropathy
• Proximal Neuropathy

Global Neuropathic Pain Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Rechargeable
• Non-Rechargeable

Global Neuropathic Pain Market Size by Procedure & CAGR (2026-2033)

• Market Overview
• Invasive
• Non-Invasive

Global Neuropathic Pain Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Transcutaneous Electrical Nerve Stimulation
• Transcranial Magnetic Stimulation
• Respiratory Electrical Stimulation

Global Neuropathic Pain Market Size by Modality & CAGR (2026-2033)

• Market Overview
• Stationary
• Portable

Global Neuropathic Pain Market Size by Mode of Purchase & CAGR (2026-2033)

• Market Overview
• Over-the-Counter Devices
• Prescription-Based Devices

Global Neuropathic Pain Market Size by Pain Type & CAGR (2026-2033)

• Market Overview
• Peripheral Neuropathy
• Entrapment Neuropathy
• Phantom Limb Neuropathy
• Trigeminal Neuralgia
• Post Herpetic Neuralgia (PHN)
• Post Traumatic Neuropathy
• Foot Pain
• Coccydynia

Global Neuropathic Pain Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Spinal Stenosis
• Chemotherapy-Induced Peripheral Neuropathy
• Diabetic Neuropathy
• Others

Global Neuropathic Pain Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Imaging
• Blood Tests
• Physical Examination

Global Neuropathic Pain Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Medications
• Multimodal Therapy

Global Neuropathic Pain Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Home Healthcare
• Ambulatory Surgical Centers
• Research Organization
• Others

Global Neuropathic Pain Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Direct Tender
• Third Party Distributor
• Others

Global Neuropathic Pain Market Size & CAGR (2026-2033)

• North America (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grunenthal GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations